Influenza places a substantial burden on the health of people in the United States each year, with varying impact. The Centers for Disease Control and Prevention estimates that influenza has resulted in between 9 million and 45 million illnesses, between 140,000 and 810,000 hospitalizations, and between 12,000 and 61,000 deaths annually since 2010. Primary care providers, nurse practitioners, physician assistants, pharmacists, and other health care professionals can identify and help manage influenza in the community. Clinical trials and observational data show that early antiviral treatment can shorten the duration of fever and illness symptoms and may reduce the risk of complications from influenza. Clinicians who evaluate patients must keep apprised of new information regarding the diagnosis and treatment of influenza so they can incorporate this information into practice, reducing patient morbidity and mortality. Three classes of antiviral drugs are currently available for the prevention and treatment of influenza: neuraminidase inhibitors, adamantanes (although adamantanes are not recommended for use in the United States), and the polymerase inhibitor baloxavir marboxil. This CME/CPE/AANP/AAPA meeting series “Flu Forum: Are You Ready for the 2020-2021 Season?” will continue to explore strategies for early diagnosis of influenza using evidence-based guidelines as well as selection of the most appropriate treatment of influenza based on its safety, efficacy, and its ability to reduce complications in patients at normal or at high risk. Clinical cases will be presented to highlight the key educational objectives.
||Improving Early Treatment Through Prompt Diagnosis
||Flu Treatment: Are You Ready for the 2021 Season?
||Case Challenges in Flu
||Question and Answer
The intended audience for this activity is family practice physicians, internists, pharmacists, nurse practitioners, physician assistants and other health care professionals involved in the management of patients with influenza.
Upon successful completion of this activity, participants should be better able to:
- Diagnose patients with influenza infection early by using evidence-based guidelines and best practices.
- Select the most appropriate treatment for patients with influenza based on its safety, efficacy, and its ability to reduce complications in patients at normal or at high risk for complications.
Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Vindico Medical Education is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education.
Vindico Medical Education designates this live activity for a maximum of 1.25 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This program is acceptable for 1.25 contact hours of ACPE Continuing Education Credit. The ACPE Universal Program Number 0482-0000-20-009-L01-P, effective 10/20/2020. This is a knowledge-based activity and there is no fee to attend.
This activity is approved for 1.25 contact hour(s) of continuing education (which includes 0.6 hours of pharmacology) by the American Association of Nurse Practitioners. Activity ID 20104555. This activity was planned in accordance with AANP Accreditation Standards and Policies.
This activity has been reviewed by the AAPA Review Panel and is compliant with AAPA CME Criteria. This activity is designated for 1.25 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation. Approval is valid from 10/20/2020 to 11/22/2020. AAPA reference number: CME-201356.
Unlabeled and Investigational Usage
The audience is advised that this activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage.
In compliance with the Americans with Disabilities Act of 1990, we will make all reasonable efforts to accommodate persons with disabilities.
Disclaimer – Vindico Medical Education
The material presented at or in any Vindico Medical Education continuing education activity does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the FDA. All readers and continuing education participants should verify all information before treating patients or utilizing any product.
Faculty, topics, program schedule, and credit hours are subject to change. Audiotaping or videotaping is prohibited without written permission from the program director and the Office of Medical Affairs and Compliance.